D.E. Shaw & Co’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q3 | – | Sell |
-6,075
| Closed | -$619K | – | 4608 |
|
|
2023
Q2 | $619K | Sell |
6,075
-87,341
| -93% | -$8.27M | ﹤0.01% | 3331 |
|
|
2023
Q1 | $8.49M | Sell |
93,416
-228,467
| -71% | -$13.4M | 0.01% | 1497 |
|
|
2022
Q4 | $12.2M | Buy |
321,883
+156,053
| +94% | +$5.37M | 0.01% | 1275 |
|
|
2022
Q3 | $4.17M | Sell |
165,830
-93,825
| -36% | -$2.6M | 0.01% | 2294 |
|
|
2022
Q2 | $7.89M | Buy |
259,655
+203,765
| +365% | +$6.08M | 0.01% | 1623 |
|
|
2022
Q1 | $1.83M | Buy |
55,890
+7,761
| +16% | +$230K | ﹤0.01% | 3393 |
|
|
2021
Q4 | $1.27M | Buy |
+48,129
| New | +$3.72M | ﹤0.01% | 3745 |
|
|
2020
Q4 | – | Sell |
-5,720
| Closed | -$557K | – | 4227 |
|
|
2020
Q3 | $557K | Sell |
5,720
-16,125
| -74% | -$2.01M | ﹤0.01% | 3174 |
|
|
2020
Q2 | $3.41M | Buy |
21,845
+19,080
| +690% | +$2.9M | ﹤0.01% | 1974 |
|
|
2020
Q1 | $399K | Buy |
+2,765
| New | +$534K | ﹤0.01% | 3317 |
|
|
2019
Q4 | – | Sell |
-4,300
| Closed | -$784K | – | 4229 |
|
|
2019
Q3 | $345K | Buy |
+4,300
| New | +$365K | ﹤0.01% | 3387 |
|
|
2019
Q2 | – | Sell |
-24,329
| Closed | -$2.1M | – | 3938 |
|
|
2019
Q1 | $2.08M | Buy |
24,329
+5,133
| +27% | +$426K | ﹤0.01% | 2138 |
|
|
2018
Q4 | $1.08M | Sell |
19,196
-26,823
| -58% | -$1.64M | ﹤0.01% | 2605 |
|
|
2018
Q3 | $3.76M | Buy |
+46,019
| New | +$3.24M | ﹤0.01% | 1756 |
|
Other funds holding RETA
D.E. Shaw & Co's RETA Position: Q3 2023 in Review
D.E. Shaw & Co sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q3 2023, closing a stake of 6,075 shares — an estimated $619K sold.
D.E. Shaw & Co first reported a position in RETA in Q3 2018 and held it in 14 quarters. The position peaked at $12.2M in Q4 2022. 2 funds tracked by Wall St. Rank hold RETA as of Q3 2023.
- D.E. Shaw & Co reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q3 2023 after selling out during the quarter.
- D.E. Shaw & Co sold 6,075 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q3 2023, an estimated $619K.
- D.E. Shaw & Co first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q3 2018 and held it in 14 quarters.
- D.E. Shaw & Co's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $12.2M in Q4 2022.
- 2 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q3 2023.
Based on D.E. Shaw & Co's 13F filing for Q3 2023, filed 14 Nov 2023.